uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 31 employees to incentivize their employment, as per Nasdaq Listing Rule 5635(c)(4). The awards include 63,300 restricted share units (RSUs) and options for 57,500 ordinary shares, with an exercise price of $20.06, reflecting the closing price on the grant date of February 23, 2023. Options will vest over four years, with one-quarter vesting after the first year and the remainder in quarterly installments. RSUs will vest over three years. This initiative is part of uniQure's strategy to attract talent as it advances its gene therapy pipeline targeting severe diseases.

Positive

• Equity awards granted to 31 employees, enhancing talent retention.
• Total of 120,800 shares granted (RSUs and options), promoting employee engagement.
• The exercise price of $20.06 reflects a solid market valuation as of the grant date.

Negative

• None.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment. The equity awards were approved by the Company’s board of directors on February 23, 2023 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the employees received 63,300 restricted share units (“RSUs”) and options to purchase 57,500 ordinary shares of the Company. Each option has an exercise price of $20.06 per share, the closing price per ordinary share as reported by Nasdaq on February 23, 2023. Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters thereafter. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date. The vesting of each option and RSU is subject to the employee’s continued service with the Company through the applicable vesting dates.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represents a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:
FOR INVESTORS:	FOR MEDIA:
Chiara Russo Direct: 617-306-9137 Mobile: 617-306-9137 c.russo@uniQure.com	Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 t.malone@uniQure.com

FAQ

What recent equity awards were announced by uniQure on March 13, 2023?

uniQure announced equity awards to 31 employees, including 63,300 RSUs and options for 57,500 shares.

What is the exercise price of the options granted to employees?

The exercise price for the options is $20.06 per share, based on the closing price on February 23, 2023.

How long is the vesting period for the equity awards granted by uniQure?

The options will vest over four years, while the RSUs will vest over three years.

What is the significance of the equity awards for uniQure's business strategy?

The equity awards are aimed at attracting and retaining talent as uniQure advances its gene therapy pipeline.